Analysis of the reasons for DMARD therapy discontinuation in patients with rheumatoid arthritis in the Czech and Slovak Republics

Clinical Rheumatology

Volumn 21, Issue 3, 2002, Pages 220-226

  Pavelka, K ^a   Forejtova S ^a   Pavelkova A ^a   Zvarova J ^b   Rovensk, J ^c   Tuchynova A ^c  

^a INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c NATIONAL INSTITUTE OF RHEUMATIC DISEASES   (Slovakia)

Author keywords

Adverse effects; Disease modifying drugs; DMARDs; Rheumatoid arthritis; Therapy

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GOLD; METHOTREXATE; PENICILLAMINE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; STEROID;

ADULT; ALLERGY; ARTICLE; CLINICAL PRACTICE; CONTINUING EDUCATION; CONTROLLED STUDY; CZECH REPUBLIC; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; EUROPE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL SPECIALIST; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SKIN DISEASE; SLOVAKIA; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CZECH REPUBLIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SLOVAKIA; TREATMENT FAILURE;

EID: 0036061677     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-002-8289-0     Document Type: Article

References (18)

1. Early aggressive DMARDs therapy: The key to slowing disease progression in rheumatoid arthritis
2. Disease-modifying antirheumatic drug use according to the "sawtooth" treatment improves the functional outcome in rheumatoid arthritis: Results of long term follow-up study with review of literature
3. Radiographic outcome of recent-onset rheumatoid arthritis. A 19-year study of radiographic progression
4. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomized trial
5. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methothrexate
6. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
7. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis
8. Aggressive treatment in early rheumatoid arthritis: A randomized controlled trial
9. Rheumatoid arthritis in Sweden. Drug prescriptions, costs and adverse drug reactions
10. Long term experience with low dose weekly methotrexate in rheumatoid arthritis
11. Long term prospective study of methotrexate in the treatment of rheumatoid arthritis
12. Factors influencing length of time taking methotrexate in rheumatoid arthritis
13. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year-old prospective evaluation of 1017 consecutive starts
14. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome-analysis of 122 studies
15. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: Some explanation and suggestions for future studies
16. Use of short-term efficacy/ toxicity tradeoffs to select second-line drugs in rheumatoid arthritis
17. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis
18. Response to sulfasalazine in rheumatoid arthritis: Life table analysis of a 5-year follow-up